RHYTHM PHARMACEUTICALS, INC.
RYTMNasdaq
$106.60
↑ +0.5%Jul 17 close · end-of-day
Price
1Y↑ +16.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$7.2B
Enterprise Value
$7.0B
P/E
—
P/S
33.4
P/B
59.0
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$217.2M
Net Income (TTM)
-$6.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-90.9%
Net Margin
-2.9%
ROE
-5.2%
ROIC
—
Debt / Equity
0.9
Net Cash
$232.2M
Return 1Y
+17.6%
Company profile
Rhythm Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency.
- CEO
- David P. Meeker
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 140
- Headquarters
- Massachusetts
- Website
- rhythmtx.com
Management & directors
- Garfield AlastairChief Scientific Officer
- Smith Hunter CChief Financial Officer
- German Christopher PaulCorporate Controller & CAO
- Mazabraud YannEVP, Head of International
- Chien JenniferEVP, Head of North America
- Cramer Pamela J.Chief Human Resources Officer
- Meeker David PPresident and CEO
- Shulman JosephChief Technical Officer
Roles derived from SEC Form 4 filings.
Earnings
RYTM Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$60.1M↑ +83.8%
Diluted EPS-$0.83↑ +2.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $3.2M | $23.6M | $77.4M | $130.1M | $189.8M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$136.6M | -$170.1M | -$179.2M | -$184.4M | -$265.5M | -$192.0M |
| Net income | -$134.0M | -$69,612.00 | -$181,119.00 | -$184,678.00 | -$260,602.00 | -$196,539.00 |
| Diluted EPS | -$3.04 | -$1.40 | -$3.47 | -$3.20 | -$4.34 | -$3.11 |
| Operating cash flow | -$122.0M | -$146.0M | -$173.4M | -$136.2M | -$113.9M | -$115.7M |
| Free cash flow | -$122.2M | -$146.4M | -$173.7M | -$136.2M | -$113.9M | -$116.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -5391.9% | -757.9% | -238.1% | -204.0% | -101.2% |
| Net margin | — | -2.2% | -0.8% | -0.2% | -0.2% | -0.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $29.1M | $33.3M | $41.8M | $32.7M | $48.5M | $51.3M | $57.3M | $60.1M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$40.5M | -$43.9M | -$41.3M | -$47.0M | -$45.3M | -$52.7M | -$47.1M | -$52.4M |
| Net income | -$32.3M | -$43.6M | $217.0M | -$49.5M | -$46.6M | -$52.9M | $148.8M | -$55.6M |
| Diluted EPS | -$0.55 | -$0.73 | -$0.71 | -$0.81 | -$0.75 | -$0.82 | -$0.73 | -$0.83 |
| Operating cash flow | -$29.1M | -$25.2M | -$18.8M | -$40.4M | -$23.3M | -$26.6M | -$25.4M | -$44.2M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -139.2% | -132.0% | -98.6% | -143.7% | -93.4% | -102.6% | -82.2% | -87.1% |
| Net margin | -110.9% | -131.2% | 518.8% | -151.4% | -96.1% | -103.1% | 260.0% | -92.6% |
Company news
Jun 29, 2026
Jun 22, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Garfield Alastair· Chief Scientific Officer | Tax withholding | 2,150 | $110.41 | $237,381.50 | filing |
| 2026-07-01 | Garfield Alastair· Chief Scientific Officer | Option exercise | 4,445 | — | — | filing |
| 2026-06-23 | MCGIRR DAVID W J | Option exercise | 4,712 | — | — | filing |
| 2026-06-23 | TETRAULT LYNN A. | Option exercise | 4,712 | — | — | filing |
| 2026-06-23 | GOOD JENNIFER L | Option exercise | 4,712 | — | — | filing |
| 2026-06-23 | Arbuckle Stuart A | Option exercise | 4,712 | — | — | filing |
| 2026-06-23 | JEAN CHRISTOPHE | Option exercise | 4,712 | — | — | filing |
| 2026-06-22 | TETRAULT LYNN A. | Sale | 37,000 | $100.32 | $3.7M | filing |
| 2026-06-22 | TETRAULT LYNN A. | Option exercise | 37,000 | $28.27 | $1.0M | filing |
| 2026-05-18 | Smith Hunter C· Chief Financial Officer | Option exercise | 3,000 | $17.87 | $53,610.00 | filing |
| 2026-05-15 | German Christopher Paul· Corporate Controller & CAO | Sale | 4,643 | $92.21 | $428,131.03 | filing |
| 2026-05-15 | German Christopher Paul· Corporate Controller & CAO | Option exercise | 1,687 | $56.69 | $95,636.03 | filing |
| 2026-05-15 | German Christopher Paul· Corporate Controller & CAO | Option exercise | 1,349 | $49.23 | $66,411.27 | filing |
| 2026-05-15 | German Christopher Paul· Corporate Controller & CAO | Option exercise | 1,406 | $17.97 | $25,265.82 | filing |
| 2026-04-01 | Mazabraud Yann· EVP, Head of International | Option exercise | 12,875 | — | — | filing |
| 2026-03-12 | Mathers Edward T | J | 4,199 | $0.00 | $0.00 | filing |
| 2026-03-04 | German Christopher Paul· Corporate Controller & CAO | Sale | 5,614 | $89.56 | $502,789.84 | filing |
| 2026-03-04 | German Christopher Paul· Corporate Controller & CAO | Option exercise | 1,500 | $17.97 | $26,955.00 | filing |
| 2026-03-02 | Smith Hunter C· Chief Financial Officer | Option exercise | 6,099 | $6.80 | $41,473.20 | filing |
| 2026-03-02 | Mathers Edward T | J | 4,198 | $0.00 | $0.00 | filing |
| 2026-03-01 | German Christopher Paul· Corporate Controller & CAO | Tax withholding | 342 | $94.94 | $32,469.48 | filing |
| 2026-03-01 | German Christopher Paul· Corporate Controller & CAO | Option exercise | 1,162 | — | — | filing |
| 2026-02-19 | Smith Hunter C· Chief Financial Officer | Sale | 1,692 | $100.92 | $170,754.78 | filing |
| 2026-02-19 | Smith Hunter C· Chief Financial Officer | Sale | 1,308 | $100.27 | $131,152.90 | filing |
| 2026-02-19 | Smith Hunter C· Chief Financial Officer | Sale | 800 | $102.10 | $81,676.08 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.